Mikhail Kalinichev has rejoined Addex Therapeutics Ltd as head of translational science as the Switzerland-based company advances its lead product in a registration trial for levodopa induced dyskinesia in Parkinson’s disease. Dr Kalinichev was most recently director of in vivo neurology at Ipsen SA where he initiated collaborations in the areas of neuromuscular disorders and pain. This follows a period at H. Lundbeck A/S where he helped oversee the clinical development of compounds for schizophrenia-related cognitive impairment and chronic pain. Before Lundbeck, he was an executive at Addex. Dr Kalinichev earned a PhD in behavioural neuroscience at Rutgers University in the US.
Addex announced the appointment on 2 August 2021.